Pradaxa Litigation Set for Settlement

Daniels Tredennick Pharmaceutical and Mass Torts

Boehringer Ingelheim Pharmaceuticals, Inc. and its affiliated companies, and the Plaintiffs’ Steering Committee appointed by a federal judge to coordinate litigation involving Pradaxa in In Re Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL No. 2385, today negotiated a settlement program to resolve the claims of approximately 4,000 Pradaxa users who claimed to have been injured by the drug. Pradaxa, an …

Study of Drug for Blood Clots Caused a Stir, Records Show

Daniels Tredennick Pharmaceutical and Mass Torts

The New York Times is reporting Boehringer Ingelheim, makers of the blood-thinning drug Pradaxa, were so worried that an internal research paper would damage drug sales that some employees not only pressured the author to revise it, but suggested it should be quashed altogether, according to newly unsealed legal documents. The documents were made public last week by a federal …